BPH & Lower Urinary Tract
Clinical Evaluation
Urinary symptoms should not dictate your sleep, travel, or daily schedule. Center for Men’s Health Rhode Island provides guideline-concordant diagnostic evaluation and individualized management planning for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
Validated IPSS Scoring • Differential Urological Workups • Sexual-Function-Conscious Management
Urinary Symptoms Deserve A Real Evaluation
Benign prostatic hyperplasia (BPH) is a non-malignant histological proliferation of prostatic stromal and epithelial cells within the transition zone surrounding the prostatic urethra. As prostate volume increases—and prostatic smooth muscle tone tightens via alpha-1 adrenergic signaling—bladder outlet resistance rises, forcing the detrusor muscle to work harder.
In accordance with American Urological Association (AUA) Clinical Practice Guidelines, lower urinary tract symptoms (LUTS) are not exclusive to BPH; they may also reflect detrusor overactivity, prostatitis, urethral stricture, neurogenic bladder dysfunction, nocturnal polyuria, or medication side effects—making a structured differential diagnosis essential prior to initiating therapy.
Quantifying Severity & Prostate Health
Our diagnostic workup establishes an objective baseline using the validated International Prostate Symptom Score (IPSS) and quality-of-life index, paired with a focused medical history, medication review (such as decongestants, anticholinergics, or diuretics), and physical examination.
When clinically indicated, evaluation incorporates urinalysis to exclude infection or hematuria, serum Prostate-Specific Antigen (PSA) screening, renal function biomarkers, and coordination of post-void residual (PVR) or urological imaging studies.
Schedule Diagnostic WorkupHow We Approach Your Care
Structured diagnostic evaluation and individualized management planning with an emphasis on shared decision-making and sexual-function preservation.
Comprehensive Differential Evaluation
We evaluate your IPSS symptom profile, medical history, and current medications—contextualizing prostate health alongside endocrine, metabolic, and cardiovascular factors.
Individualized Management Planning
Care plans integrate behavioral fluid and bladder strategies, evidence-based pharmacotherapy tailored to protect sexual function, or coordinated referral for surgical/minimally invasive urological procedures.
Longitudinal Surveillance
We track longitudinal IPSS score improvements, monitor PSA velocity and blood pressure, screen for medication side effects (such as orthostasis or ejaculatory changes), and adjust your regimen over time.
Therapeutic Management Classes
Medical management is tailored to symptom severity, prostate volume, and co-existing sexual or cardiovascular considerations.
Selective Alpha-1 Adrenergic Antagonists
First-line agents that relax smooth muscle tone in the prostate stroma and bladder neck to rapidly improve urinary flow rate, selected carefully to balance blood pressure and ejaculatory function.
Daily PDE5 Inhibitor Therapy
FDA-approved daily phosphodiesterase type 5 inhibition (Tadalafil) relaxes lower urinary tract smooth muscle while simultaneously supporting cavernous endothelial function in men with co-occurring LUTS/BPH and erectile dysfunction.
5-Alpha-Reductase Inhibitors & Combination Care
For men with demonstrably enlarged prostate volume, 5-ARIs inhibit intraprostatic conversion of testosterone to dihydrotestosterone (DHT) to reduce glandular bulk—always preceded by thorough counseling regarding potential sexual side effects and PSA interpretation.
Watchful Waiting & Urological Referral
Structured lifestyle and evening fluid-timing protocols for mild LUTS (IPSS 0–7), alongside seamless clinical coordination with surgical urologists when minimally invasive surgical therapies (MIST) or procedural intervention are indicated.
Insurance & Self-Pay Options
Clear billing pathways for prostate evaluations, diagnostic laboratory testing, and ongoing clinical follow-up.
Commercial Insurance Accepted
We accept a wide range of insurance plans for BPH evaluations, urinalysis, and PSA laboratory diagnostics. Our administrative staff assists with benefit verification and authorization requirements where applicable.
Direct Self-Pay Options
Transparent self-pay options are available for patients who prefer not to use insurance or whose specific service is not covered. Contact our Providence office for current pricing before scheduling.
Clinical Guidelines & Medical Disclosures
Our evaluation and management of lower urinary tract symptoms are anchored in peer-reviewed urological guidelines.
Primary Urological Practice Guidelines & Federal Sources
- American Urological Association (AUA) — Management of Lower Urinary Tract Symptoms Attributed to BPH: Sandhu JS, Bixler BR, Dahm P, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. Journal of Urology. View AUA BPH Clinical Guideline ↗
- American Urological Association (AUA) — Early Detection of Prostate Cancer: Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline. Journal of Urology. View AUA Prostate Cancer Screening Guideline ↗
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK / NIH): Evidence-based clinical overview of Benign Prostatic Hyperplasia pathophysiology, diagnostic testing, and medical management. View NIH / NIDDK Clinical Resource ↗
- U.S. Food & Drug Administration (FDA): Approved prescribing indications and safety labeling for alpha-1 adrenergic blockers, 5-alpha-reductase inhibitors, and daily phosphodiesterase type 5 inhibitors (Tadalafil) in the management of signs and symptoms of BPH. View FDA Drug Labeling Database ↗
Medical & Acute Urinary Retention Disclaimer: This content is provided strictly for educational and informational purposes and is not a substitute for individualized medical advice, diagnosis, or treatment. Lower urinary tract symptoms have multiple possible etiologies—including benign prostatic hyperplasia, infection, bladder dysfunction, calculi, or malignancy—and require evaluation by a licensed healthcare professional. If you experience acute urinary retention (inability to urinate), severe lower abdominal or flank pain, visible blood in the urine (gross hematuria), or fever/chills accompanying urinary symptoms, seek emergency medical attention immediately.
Scope of Care & Surgical Referral Notice: Treatment options, eligibility, risks, and outcomes vary by individual. Certain diagnostic findings (such as elevated PSA, suspected malignancy, refractory urinary retention, bladder calculi, or upper tract renal insufficiency) or preferences for minimally invasive surgical therapies (MIST) require referral to a board-certified surgical urologist. Review our full Clinical Transparency & Pharmacy Disclosures and Terms of Service.